Merck KGaA (MEX:MRK1N) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MRK1N Merck KGaA MEX:MRK1N
84 GF Score
Price MXN3,299.85
GF Value MXN3,580.00
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Merck KGaA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN21,856 Mil. Merck KGaA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN223,910 Mil. Merck KGaA's annualized EBITDA for the quarter that ended in Jun. 2026 was MXN108,409 Mil. Merck KGaA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 2.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Merck KGaA's Debt-to-EBITDA or its related term are showing as below:

MEX:MRK1N' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.59   Med: 2.21   Max: 3.16
Current: 2.25

During the past 13 years, the highest Debt-to-EBITDA Ratio of Merck KGaA was 3.16. The lowest was 1.59. And the median was 2.21.

MEX:MRK1N's Debt-to-EBITDA is ranked worse than
59.68% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs MEX:MRK1N: 2.25

Merck KGaA  (MEX:MRK1N) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Merck KGaA Debt-to-EBITDA Related Terms

Merck KGaA Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Debt-to-EBITDA Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:MRK1N vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck KGaA Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Debt-to-EBITDA falls into.


MEX:MRK1N
84GF Score
Merck KGaA MEX:MRK1N
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Merck KGaA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(26141.63743345 + 226574.93510575) / 118096.70328102
=2.14

Merck KGaA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(21855.64578225 + 223910.491707) / 108409.01236605
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Merck KGaA (MEX:MRK1N) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of MXN3,299.85 is trading 7.8% below its estimated GF Value™ of MXN3,580.00.

Key valuation signals for MEX:MRK1N:

  • Debt-to-EBITDA:
  • GF Value™: MXN3,580.00 vs. price of MXN3,299.85 (7.8% below fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the MEX:MRK1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for MEX:MRK1N

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,299.85
Price
MXN3,580.00
GF Value